Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions, epilepsy-related syndrome, and the like as described herein.

The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions, epilepsy-related syndrome, and the like as described herein.

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

The present invention relates to 1,2,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive signal induced by PD-1, PD-L1 or PD-L2.

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

This disclosure features compounds and compositions for use in methods of treating iatrogenic autoimmune colitis in a subject in need thereof, e.g., iatrogenic autoimmune colitis induced by one or more chemotherapeutic agents (e.g., a chemotherapeutic immunomodulatory; e.g., an immune checkpoint inhibitor; e.g., an immune checkpoint inhibitor that targets CTLA-4). The methods Include administering to the subject one or more chemical entities including, but not limited to, sphingosine 1-phosphate (S1P) receptor modulators; Janus kinase (JAK) inhibitors; lanthionine synthetase C-like 2 (LANCL2) modulators; integrin modulators; and immunosuppressants (e.g., cyclosporine).

This disclosure features compounds and compositions for use in methods of treating iatrogenic autoimmune colitis in a subject in need thereof, e.g., iatrogenic autoimmune colitis induced by one or more chemotherapeutic agents (e.g., a chemotherapeutic immunomodulatory; e.g., an immune checkpoint inhibitor; e.g., an immune checkpoint inhibitor that targets CTLA-4). The methods Include administering to the subject one or more chemical entities including, but not limited to, sphingosine 1-phosphate (S1P) receptor modulators; Janus kinase (JAK) inhibitors; lanthionine synthetase C-like 2 (LANCL2) modulators; integrin modulators; and immunosuppressants (e.g., cyclosporine).

This disclosure features compounds and compositions for use in methods of treating iatrogenic autoimmune colitis in a subject in need thereof, e.g., iatrogenic autoimmune colitis induced by one or more chemotherapeutic agents (e.g., a chemotherapeutic immunomodulatory; e.g., an immune checkpoint inhibitor; e.g., an immune checkpoint inhibitor that targets CTLA-4). The methods Include administering to the subject one or more chemical entities including, but not limited to, sphingosine 1-phosphate (S1P) receptor modulators; Janus kinase (JAK) inhibitors; lanthionine synthetase C-like 2 (LANCL2) modulators; integrin modulators; and immunosuppressants (e.g., cyclosporine).